Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells

Chinese Medical Journal

Volumn 123, Issue 13, 2010, Pages 1768-1773

  Yang, Guo Fu ^a   Li, Xiang Hui ^b   Zhao, Zhe ^a   Wang, Wen Bo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Fas; Fas ligand; Matrix metalloproteinase 7; Saos 2

Indexed keywords

ARSENIC TRIOXIDE; CELL DNA; FAS ANTIGEN; FAS LIGAND; MATRILYSIN; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSCRIPTION TERMINATION; WESTERN BLOTTING;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; OSTEOSARCOMA; OXIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77954461051     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.13.028     Document Type: Article

References (20)

1. Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES, et al. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res 2005; 3: 685-690
2. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: Osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr 2009; 21: 365-372
3. Worth LL, Lafleur EA, Jia S-F, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002; 9: 823-827
4. Li XS, Li WQ, Wang WB. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment. Cancer Biother Radiopharm 2007; 22: 772-778
5. Guo W, Tang XD, Tang S, Yang Y. Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Chin J Surg (Chin) 2006; 44: 805-808
6. Jung HS, Kim HS, Lee MJ, Shin HY, Ahn HS, Ryu KH, et al. Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro. FEBS Lett 2006: 4969-4975
7. Mathieu J, Besancon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer 2006; 119: 1723-1727
8. Zhukalin M, Blanksma MK, Silva TD, Suyehira SW, Harvey WA, Heqqland SJ, et al. Characterization and in vitro cytotoxicity testing of ethanolamine-derived cadmium chelating agents. Biometals 2007; 20: 61-72
9. Fridlender ZG, Cohen PY, Golan O, Arish N, Wallach-Dayan S, Breuer R. Telomerase activity in bleomycin-induced epithelial cell apoptosis and lung fibrosis. Eur Respir J 2007; 30: 205-213
10. Chen H, Takahashi S, Imamura M, Okutani E, Zhang ZG, Chayama K, et al. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo. Chin Med J 2007; 120: 898-904
11. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005; 5: 12.
12. Rikhof B, van der Graaf WT, Meijer C, Le PT, Meersma GJ, de Jong S, et al. Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer 2008; 99: 1600-1606
13. Itoh K, Hase H, Kojima H, Saotome K, Nishioka K, Kobata T. Central role of mitochondria and p53 in Fas-mediated apoptosis of rheumatoid synovial fibroblasts. Rheumatology 2004; 43: 277-285
14. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-581
15. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001; 61: 4066-4071
16. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 1998; 153: 1947-1956
17. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999; 9: 1441-1447
18. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17: 501-506
19. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004; 10: 8114-8119
20. Zhao H, Guo W, Peng C, Ji T, Lu X. Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis. Mol Biol Rep 2009; Epub ahead of print.